Skip to main content
. 2012 Dec 20;108(2):334–341. doi: 10.1038/bjc.2012.539

Figure 6.

Figure 6

Anti-angiogenic effect. (A) Blood vessels were detected by immunohistological staining of CD31-positive endothelial cells (red) in sorafenib-, sorafenib/CDDP-treated and untreated mice. The blue HE staining denotes HB cells. (B) Treatment with sorafenib alone and to a higher degree in combination with CDDP resulted in a significant decrease of CD31-positive endothelial cells as estimated by the mean vascular density (MVD). Means, s.d., and confidential intervals (95%) for each group (*, **P=0.02, n=4, Student's t-test) are shown.